S&P 500 cuts losses as Nvidia climbs ahead of results
SHELTON, Conn. - Intensity Therapeutics, Inc. (Nasdaq:INTS), a micro-cap biotech company currently valued at $12.7 million, has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, according to a company announcement Tuesday. According to InvestingPro data, the stock has experienced significant volatility, declining over 84% year-to-date to its current price of $0.27.
The clinical-stage biotechnology company, which develops intratumoral cancer therapies, received confirmation from Nasdaq’s Listing Qualifications Staff on August 8 that it had met the $2.5 million stockholders’ equity threshold.
The compliance determination followed Intensity’s August 7 filing of its quarterly report, which demonstrated sufficient stockholders’ equity based on the company’s cash position as of June 30, 2025, plus additional funds raised through July 2025.
"Based on the cash raised through July 2025, we now project to have sufficient cash to fund our current operating plan into the second half of 2026," said Lewis H. Bender, President and CEO of Intensity, in the press release statement. InvestingPro analysis shows the company maintains a healthy balance sheet with more cash than debt and a conservative debt-to-equity ratio of 0.06, though its overall Financial Health Score remains weak.
Intensity Therapeutics is currently advancing several clinical trials for its lead product candidate INT230-6, which is designed for direct injection into tumors. The company has initiated a Phase 3 trial in soft tissue sarcoma and is collaborating with the Swiss Cancer Group on a Phase 2 study in triple-negative breast cancer.
INT230-6 combines two anti-cancer agents, cisplatin and vinblastine sulfate, with a diffusion enhancer molecule that helps distribute the drugs throughout tumors. According to the company, this approach aims to kill cancer cells directly while also triggering an immune response against the tumor.
The company has previously completed two clinical studies involving over 200 patients using INT230-6, including a Phase 1/2 dose escalation study in metastatic cancers and a Phase 2 randomized control trial in locally advanced breast cancer. Discover more insights about INTS and track its clinical progress with InvestingPro, which offers 12 additional investment tips and comprehensive financial metrics for informed decision-making.
In other recent news, Intensity Therapeutics, Inc. reported its financial results for the first quarter of 2025, revealing a quarterly loss of $3.3 million, or $0.19 per share. This marks an improvement from the previous year’s loss of $4.6 million, or $0.34 per share. The company has announced a public offering of common stock, with proceeds aimed at funding ongoing clinical trials and general corporate purposes. In clinical developments, Intensity’s cancer drug INT230-6 has shown promising results in its Phase 2 INVINCIBLE-4 study, with early-stage patients achieving high levels of tumor necrosis. Additionally, Intensity Therapeutics held its annual meeting, where Mark A. Goldberg was elected as a Class II director. Analyst activity included Brookline Capital Markets downgrading the stock to a Hold rating due to concerns about the company’s financial runway. Meanwhile, Benchmark has maintained its Speculative Buy rating with a $4.00 price target. These developments come as Intensity advances its clinical trials, including a significant Phase 3 trial for INT230-6 in advanced soft tissue sarcoma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.